Morgan Stanley raised the firm’s price target on Regeneron to $1,115 from $1,104 and keeps an Overweight rating on the shares. The firm refresh its model to add 2031-2033 estimates, noting that it has raised its view of the odds of success on Dupixent for COPD to 100% from 90% and models 2033 worldwide sales of $24.9B. Looking ahead for the stock, the firm calls out a number of catalysts, including Eylea conversion to high-dose, Dupixent for treatment of COPD, Fianlimab, bispecifics for cancer and the company’s obesity program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
- Regeneron initiated with an Outperform at Bernstein
- Regeneron says FDA has extended approval of Praluent
- Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
- Regeneron published one-year results from PULSAR, PHOTON, met primary endpoint
